Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021

by Sehdev, Sandeep, Chambers, Alexandra
Published 2022

Can surveying practitioners about their practices help identify priority clinical practice guideline topics?

by Brouwers, Melissa C, Chambers, Alexandra, Perry, James
Published 2003

An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries

by Ward, Leanne Marie, Chambers, Alexandra, Mechichi, Emine, Wong-Rieger, Durhane, Campbell, Craig
Published 2022

Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?

by Cheung, Matthew C, Chan, Kelvin KW, Sabharwal, Mona, Fields, Anthony, Chambers, Alexandra, Evans, William K
Published 2017

The impact of pricing strategy on the costs of oral anti‐cancer drugs

by Truong, Judy, Chan, Kelvin K. W., Mai, Helen, Chambers, Alexandra, Sabharwal, Mona, Trudeau, Maureen E., Cheung, Matthew C.
Published 2019

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

by Chan, Kelvin, Nam, Seungree, Evans, Bill, de Oliveira, Claire, Chambers, Alexandra, Gavura, Scott, Hoch, Jeffrey, Mercer, Rebecca E, Dai, Wei Fang, Beca, Jaclyn, Tadrous, Mina, Isaranuwatchai, Wanrudee
Published 2020